Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 6,696 shares at $20.12 ($135K) on 2025-02-03, disclosed to the SEC on 2025-02-04.
Seasonal sale ($135k) by SVP, CHIEF ACCOUNTING OFFICER — this insider has traded TVTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.12 | 3,348 | $67K | 50.0% |
| 2 | $20.12 | 3,348 | $67K | 50.0% |
| Total | $20.12 avg | 6,696 | $135K | 100% |
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |